RxDoctor Payments Data

Rebecca Beyer, PA

Physician Assistant · Grafton, NDNPI 1265006878

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Amgen at 24.9% of the total. Reporting peaked in 2024 at $715 and has fallen 92.5% since, to $53 in 2025.

$1,610in general payments, 2019–2025

Across 80 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$400
  • AbbVie$138
  • Abbott$133
  • Smith+Nephew$129
  • Zimmer Biomet$114
  • Novo Nordisk$88
  • plus $608 from 16 others

What the payments were for

  • Food & beverage$1,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,610 in reported general payments places this provider in the 85th percentile of 355 physician assistant providers in North Dakota.

See all physician assistant providers in North Dakota

Medicare billing

Part B allowed, 2024
$2,472
Medicare patients
22
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$28,719
JanuviaSitagliptin Phosphate11$13,707
XareltoRivaroxaban11$6,543
OxycontinOxycodone Hcl12$3,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,060
Metoprolol Succinate74$892
Estradiol13$870
Ventolin HfaAlbuterol Sulfate11$697
Atorvastatin Calcium80$614
Omeprazole73$557
Albuterol Sulfate HfaAlbuterol Sulfate16$533
Oxybutynin Chloride ErOxybutynin Chloride14$509
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$455
Enalapril Maleate18$455
Lisinopril77$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$88$28,71928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 355 physician assistant providers in North Dakota.

Other physician assistant in Grafton

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →